Wuhan Hvsen Biotechnology Co Ltd (300871) - Total Liabilities

Latest as of June 2026: CN¥1.08 Billion CNY ≈ $158.50 Million USD

Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has total liabilities worth CN¥1.08 Billion CNY (≈ $158.50 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wuhan Hvsen Biotechnology Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Wuhan Hvsen Biotechnology Co Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Wuhan Hvsen Biotechnology Co Ltd.

Wuhan Hvsen Biotechnology Co Ltd Competitors by Total Liabilities

The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Rogers Sugar Inc. TO:RSI	Canada	CA$651.96 Million
YoungPoong KO:000670	Korea	₩1.91 Trillion
Stx Engine KO:077970	Korea	₩814.56 Billion
Shenzhen Sea Star Technology SHE:002137	China	CN¥364.05 Million
Dexterra Group Inc TO:DXT	Canada	CA$467.63 Million
Contrel Technology Co Ltd TWO:8064	Taiwan	NT$2.14 Billion
QITIAN Technology Group Co Ltd SHE:300061	China	CN¥684.65 Million
BCI Minerals Limited F:BC3	Germany	€767.00 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Wuhan Hvsen Biotechnology Co Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.05	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.47	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Wuhan Hvsen Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)

The table below shows the annual total liabilities of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥822.17 Million ≈ $120.31 Million	-46.94%
2024-12-31	CN¥1.55 Billion ≈ $226.74 Million	+5.68%
2023-12-31	CN¥1.47 Billion ≈ $214.55 Million	+1.28%
2022-12-31	CN¥1.45 Billion ≈ $211.84 Million	+28.93%
2021-12-31	CN¥1.12 Billion ≈ $164.30 Million	+200.96%
2020-12-31	CN¥373.08 Million ≈ $54.59 Million	+37.26%
2019-12-31	CN¥271.80 Million ≈ $39.77 Million	+91.30%
2018-12-31	CN¥142.08 Million ≈ $20.79 Million	+17.36%
2017-12-31	CN¥121.06 Million ≈ $17.72 Million	+19.67%
2016-12-31	CN¥101.16 Million ≈ $14.80 Million	--

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology

Market Cap

$629.52 Million

CN¥4.30 Billion CNY

Market Cap Rank

#11099 Global

#3069 in China

Share Price

CN¥21.32

Change (1 day)

-0.56%

52-Week Range

CN¥19.24 - CN¥32.62

All Time High

CN¥48.84